Gabapentin Tablet
Product Images NDC 68788-8468

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8468). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Tablets Usp 800mg (180b99a5 7d3d 4ee5 A0cc 1ae0ede646ee 00)

Label for Gabapentin Tablets USP 800 mg oral tablets by Preferred Pharmaceuticals Inc. The label includes dosing instructions in English and Spanish on a yellow background, and states the tablets are generic for Neurontin. Manufacturer is listed as Ascent Pharmaceuticals, Inc. Additional packaging details like lot and expiration dates are present but not filled in.*

FDA Label Image

Sideeffects (Sideeffects)

Partial text panel listing possible symptoms or side effects associated with a medication. The visible text includes symptoms such as lack of coordination, viral infection, difficulty speaking, tremor, swelling of legs and feet, tiredness, fever, drowsiness, nausea and vomiting, jerky movements, difficulty with coordination, double vision, and unusual eye movement.*

FDA Label Image

Table-1 (Table1)

A data table titled 'Gabapentin Dosage Based on Renal Function' showing dosage recommendations for Gabapentin tablets based on creatinine clearance levels in mL/min. The table lists total daily dose ranges in mg/day and specific dose regimens (mg) by frequency such as TID, BID, and QD for different renal function categories including post-hemodialysis supplemental doses in mg.*

FDA Label Image

Table-2 (Table2)

A data table titled 'Risk by Indication for Antiepileptic Drugs in the Pooled Analysis,' showing risk measurements for placebo and drug patients across indications including Epilepsy, Psychiatric, and Other. It presents events per 1,000 patients, relative risk, and risk difference values for each indication and totals.*

FDA Label Image

Table-3 (Table3)

A data table titled 'Adverse Reactions in Pooled Placebo-Controlled Trials in Postherpetic Neuralgia' comparing the percentage incidence of various adverse reactions between Gabapentin (N=336) and Placebo (N=227). Adverse reactions are grouped by body systems such as Body as a Whole, Digestive System, Metabolic and Nutritional Disorders, Nervous System, Respiratory System, and Special Senses.*

FDA Label Image

Table-4 (Table4)

Table titled 'Adverse Reactions in Pooled Placebo-Controlled Add-On Trials in Epilepsy Patients >12 years of age' listing adverse reactions by body system for Gabapentin versus placebo. It presents the incidence percentages for various reactions such as fatigue, somnolence, dizziness, and diplopia among others in patients taking Gabapentin (N=543) compared to placebo (N=378).*

FDA Label Image

Table-5 (Table5)

A table showing adverse reactions in a placebo-controlled add-on trial of gabapentin in pediatric epilepsy patients aged 3 to 12 years. It lists various adverse reactions by system (body as a whole, digestive, nervous, respiratory) and provides percentage incidences for both a gabapentin group (N=119) and a placebo group (N=128).*

FDA Label Image

Table-6 (Table6)

A data table titled 'Controlled PHN Studies: Duration, Dosages, and Number of Patients' presenting study duration in weeks, gabapentin target dose in mg/day, and patient counts receiving gabapentin or placebo across two studies, with a total patient count summarized. A footnote notes dosing is given in 3 divided doses (TID).*

FDA Label Image

Clcr (Clcr)

An illustration showing the formula to estimate creatinine clearance (CLCr), calculated using age, weight, and serum creatinine levels, with a multiplication factor adjustment for female patients.*

FDA Label Image

Figure-1 (Figure1)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 1' comparing mean pain scores over 8 weeks between placebo and Gabapentin 3600 mg/day groups. The x-axis represents weeks, and the y-axis shows mean pain scores from 0 to 10. The graph includes a 4-week dose titration period followed by a 4-week fixed dose period, illustrating a decrease in pain scores for the Gabapentin group versus stable scores for placebo.*

FDA Label Image

Figure-2 (Figure2)

A line graph titled 'Weekly Mean Pain Scores (Observed Cases in ITT Population): Study 2' showing mean pain scores over 7 weeks. It compares three groups: Placebo, Gabapentin 1800 mg/day, and Gabapentin 2400 mg/day. The graph indicates a 3-week dose titration period followed by a 4-week fixed dose period, with pain scores decreasing more for the Gabapentin groups than placebo over time.*

FDA Label Image

Figure-3 (Figure3)

A bar chart titled 'Proportion of Responders (patients with ≥50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) and gabapentin (GBP) at various dosages in two studies. Study 1 shows 12% responder rate for placebo and 29% for GBP 3600 mg. Study 2 shows 14% for placebo, 32% for GBP 1800 mg, and 34% for GBP 2400 mg, with statistical significance indicated for gabapentin groups.*

FDA Label Image

Figure-4 (Figure4)

A scatter plot figure titled "Responder Rate in Patients Receiving Gabapentin Expressed as a Difference from Placebo by Dose and Study," showing the relationship between daily gabapentin dose (600, 900, 1200, 1800 mg) on the x-axis and responder rate difference (%) on the y-axis. The graph includes data points from three studies labeled a, b, and c, with distinct square markers and annotations for each dose group.*

FDA Label Image

Struc (Struct)

Chemical structure of gabapentin, showing a cyclohexane ring attached to a carbon bonded to an amino group (CH2NH2) and a carboxyl group (CH2CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.